In an ongoing clinical study at Helsingborg Hospital, Suturion's innovative surgical sewing machine has been used in 14 operations out of 38 planned, with excellent preliminary results. The clinical results will serve as the basis for a CE marking of the company's medtech instrument before the planned commercialization at the end of the year. The company participates in SmiLe´s incubator program.
The Suture-TOOL instrument from Suturion will likely be the first of its kind on the market, as current practice after major abdominal surgery is to close the abdominal wall by suturing by hand. Worldwide, over 30 million open abdominal surgeries are carried out annually. Swedish trauma surgeon Dr. Gabriel Börner, founder of the company, has developed an instrument to help surgeons close the abdominal wall faster and better.
In addition to infection, common and troublesome complications following abdominal wall surgery include rupture of the incision and development of hernias over time. The Suture-TOOL makes it easier to meet the guidelines of the European Hernia Society (EHS), thereby ensuring quality and reducing the risk of infection. Closure of the abdominal wall will probably also take significantly less time.
Several of the largest global medical device companies have contacted Suturion to show interest in the product well before its introduction to the market. The company is collaborating with the European Hernia Society, an international scientific organization that focuses on abdominal wall surgery and hernia prevention.
“Our earlier studies showed that Suture-TOOL significantly reduces the time it takes to suture the fascia. We believe the current study will show higher quality outcomes, while radically reducing suturing time to less than half of what is currently required. We were attracted to the incubator by the wide-ranging experience of the SmiLe coaches, for example in commercial strategies and raising capital,” says Paan Hermansson, CEO of Suturion.
“Suturion’s innovation has big potential for improving medical care, reducing suffering, and saving resources through fewer medical complications. This is a great example of how SmiLe helps innovative companies with commercialization of solutions that improve the quality of healthcare,” says Ebba Fåhraeus, CEO of SmiLe Incubator.
For more information, please contact:
Magdalena Gräff, marketing manager
firstname.lastname@example.org, +46 (0)767-878585
Ebba Fåhraeus, CEO,
email@example.com, +46 (0)73 4000433
About SmiLe Incubator SmiLe Incubator is a life science business incubator based in Medicon Village in Lund, Sweden. SmiLe offers business coaching, a broad international industry and investor network and a unique laboratory infrastructure with state-of-the art instrumentation. Since the start, SmiLe has helped 100+ entrepreneurs commercialize their business ideas. Currently there are some 30 companies in SmiLe incubator which, together with alumni companies, have attracted more than EUR 717 million in venture capital since 2014. To date, 21 of SmiLe´s companies have launched an IPO and these listed companies have a market capitalization of more than EUR 500 million (Q4 2022). SmiLe is a non-profit organization and receives basic funding from Region Skåne, Lund Municipality, Lund University and Medicon Village. SmiLe´s sponsors are Agilent, Sparbanken Skåne, Awa, Høiberg, Magle Chemoswed, Merck, Prevas, Setterwalls, Zacco, Phase Holographic Imaging and ChemoMetec. www.smileincubator.life